Effect of Chitosan oligosaccharides on ischemic symptom and gut microbiota disbalance in mice with hindlimb ischemia

Carbohydr Polym. 2020 Jul 15:240:116271. doi: 10.1016/j.carbpol.2020.116271. Epub 2020 Apr 25.

Abstract

This study was designed to explore the effect of Chitosan oligosaccharides (COS) on mouse hindlimb ischemia by femoral artery ligation. Here, we demonstrated that COS treatment statistically promoted the blood perfusion and neovascularization in ischemic hindlimb of mice, accompanied by the suppression of inflammation and oxidative stress. By 16S rDNA gene sequencing, the disbalanced gut microbiota was observed in ischemic mice, while COS treatment, at least in part, restored the abundance changes of some intestinal bacteria at either phylum or genus levels. Based on metabolomics analysis on mouse plasma by UPLC-QTOF-MS, we screened 20 metabolites with the largest responses to ischemia, several of which were markedly reversed by COS. By Spearman's correlation analysis, the changed metabolites might act as a bridge between improved intestinal bacterial structure and alleviated hindlimb ischemia of mice treated by COS. Our studies point towards a potential role of COS in treatment of peripheral ischemia diseases.

Keywords: Chitosan oligosaccharides; Lower limb ischemia; gut microbiota; inflammation; metabolomics; oxidative stress.

MeSH terms

  • Animals
  • Chitosan / therapeutic use*
  • Femoral Artery / drug effects
  • Femoral Artery / physiology
  • Gastrointestinal Microbiome / drug effects*
  • Hindlimb / drug effects*
  • Hindlimb / pathology
  • Inflammation / drug therapy
  • Ischemia / drug therapy*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Muscle, Skeletal / blood supply
  • Muscle, Skeletal / drug effects
  • Neovascularization, Physiologic / drug effects*
  • Oxidative Stress / drug effects
  • Regional Blood Flow

Substances

  • Chitosan